Medicare patients with multiple sclerosis face skyrocketing costs for treatment due to insurance regulations that force them to pay more out of pocket for generic drugs, a study has found.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
Prescription drug prices have dominated the health care agendas of Oregon lawmakers so far this session, with a Canadian importation plan among the proposals introduced into the Legislature.
Europeans have found the secret to making some of the world’s costliest medicines much more affordable, as much as 80 percent cheaper than in the U.S.
Angela Lautner knew her thirst was unusual, even for someone directing airplanes, outside in the Memphis summer heat.
The Oregon Health Authority is moving to expand treatment for hepatitis C to everyone on the Oregon Health Plan who’s infected.
Three of the lawmakers who will lead the House next year as Congress focuses on skyrocketing drug costs are among the biggest recipients of campaign contributions from the pharmaceutical industry, a new KHN analysis shows.
At the end of September, Amarin Corp. teased some early findings for Vascepa, its preventive medicine for people at risk of heart disease. The claim was astounding: a 25 percent relative risk reduction for deaths related to heart attacks, strokes and other conditions.